MedTrace Logo

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

NCT05013255 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-04-08

No results posted yet for this study

Summary

The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This represents an off-label use of this compound, both in terms of the patient population and the clinical phenotype targeted. The central research hypothesis of this study is that daily pioglitazone will restore transcriptional downregulation of pathways within skeletal that promote fatigue.

Conditions

Interventions

DRUG

Pioglitazone 15mg

PIO 15mg orally once daily for 2 weeks

DRUG

Pioglitazone 30 mg

PIO 30mg orally once daily for 2 weeks

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Kristin H Lupinacci, DO · West Virginia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05013255 on ClinicalTrials.gov